Search Results - "Köstler, W"

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions by Pradeep, C. -R, Zeisel, A., Köstler, W. J., Lauriola, M., Jacob-Hirsch, J., Haibe-Kains, B., Amariglio, N., Ben-Chetrit, N., Emde, A., Solomonov, I., Neufeld, G., Piccart, M., Sagi, I., Sotiriou, C., Rechavi, G., Domany, E., Desmedt, C., Yarden, Y.

Get full text

Open Reduction and Internal Fixation of Proximal Humeral Fractures with Use of the Locking Proximal Humerus Plate: Results of a Prospective, Multicenter, Observational Study by Südkamp, N, Bayer, J, Hepp, P, Voigt, C, Oestern, H, Kääb, M, Luo, C, Plecko, M, Wendt, K, Köstler, W, Konrad, G

“…BackgroundThe treatment of unstable displaced proximal humeral fractures, especially in the elderly, remains controversial. The objective of the present…”
Get full text

Wafer reuse for repeated growth of III-V solar cells by Bauhuis, G. J., Mulder, P., Haverkamp, E. J., Schermer, J. J., Bongers, E., Oomen, G., Köstler, W., Strobl, G.

“…The epitaxial lift‐off (ELO) technique can be used to separate a III–V solar cell structure from its underlying GaAs or Ge substrate. ELO from 4‐inch Ge wafers…”
Get full text

Third consensus on medical treatment of metastatic breast cancer by Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C. C., Zwierzina, H.

“…Background: Treatment options for patients with metastatic breast cancer (MBC) include a rapidly expanding repertoire of medical, surgical and supportive care…”
Get full text

Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression by Pareja, F, Ferraro, D A, Rubin, C, Cohen-Dvashi, H, Zhang, F, Aulmann, S, Ben-Chetrit, N, Pines, G, Navon, R, Crosetto, N, Köstler, W, Carvalho, S, Lavi, S, Schmitt, F, Dikic, I, Yakhini, Z, Sinn, P, Mills, G B, Yarden, Y

“…Once stimulated, the epidermal growth factor receptor (EGFR) undergoes self-phosphorylation, which, on the one hand, instigates signaling cascades, and on the…”
Get full text

Space Solar Cells – 3G30 and Next Generation Radiation Hard Products by Guter, W., Dunzer, F., Ebel, L., Hillerich, K., Köstler, W., Kubera, T., Meusel, M., Postels, B., Wächter, C.

“…The 3G30-Advanced, AZUR SPACE’s latest qualified solar cell product, provides highest end-of-life efficiencies in space. The cell reaches 27.8% at a fluence of…”
Get full text

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis by Lindzen, M, Carvalho, S, Starr, A, Ben-Chetrit, N, Pradeep, C-R, Köstler, W J, Rabinkov, A, Lavi, S, Bacus, S S, Yarden, Y

“…Epidermal growth factor (EGF)-like growth factors control tumor progression as well as evasion from the toxic effects of chemotherapy. Accordingly, antibodies…”
Get full text

Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions by Pradeep, C-R, Zeisel, A, Köstler, W J, Lauriola, M, Jacob-Hirsch, J, Haibe-Kains, B, Amariglio, N, Ben-Chetrit, N, Emde, A, Solomonov, I, Neufeld, G, Piccart, M, Sagi, I, Sotiriou, C, Rechavi, G, Domany, E, Desmedt, C, Yarden, Y

“…The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional…”
Get full text

Second consensus on medical treatment of metastatic breast cancer by Beslija, S., Bonneterre, J., Burstein, H., Cocquyt, V., Gnant, M., Goodwin, P., Heinemann, V., Jassem, J., Köstler, W.J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken, N., Wiltschke, C., Zielinski, C.C., Zwierzina, H.

“…The present consensus manuscript defines evidence-based recommendations for state-of-the-art treatment of metastatic breast cancer depending on…”
Get full text

Modeling ductal carcinoma in situ: a HER2–Notch3 collaboration enables luminal filling by Pradeep, C-R, Köstler, W J, Lauriola, M, Granit, R Z, Zhang, F, Jacob-Hirsch, J, Rechavi, G, Nair, H B, Hennessy, B T, Gonzalez-Angulo, A M, Tekmal, R R, Ben-Porath, I, Mills, G B, Domany, E, Yarden, Y

“…A large fraction of ductal carcinoma in situ (DCIS), a non-invasive precursor lesion of invasive breast cancer, overexpresses the HER2/neu oncogene. The ducts…”
Get full text

Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab by Bates, M., Sperinde, J., Köstler, W.J., Ali, S.M., Leitzel, K., Fuchs, E.M., Paquet, A., Lie, Y., Sherwood, T., Horvat, R., Singer, C.F., Winslow, J., Weidler, J.M., Huang, W., Lipton, A.

“…Patients with metastatic breast cancer (MBC) overexpressing HER2 (human epidermal growth factor receptor 2) are currently selected for treatment with…”
Get full text

Open Reduction and Internal Fixation of Proximal Humeral Fractures with Use of the Locking Proximal Humerus Plate: Surgical Technique by Konrad, G., Bayer, J., Hepp, P., Voigt, C., Oestern, H., Kääb, M., Luo, C., Plecko, M., Wendt, K., Köstler, W., Südkamp, N.

“…The treatment of unstable displaced proximal humeral fractures, especially in the elderly, remains controversial. The objective of the present prospective,…”
Get full text

Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations by Hudelist, G, Wagner, T, Rosner, M, Fink-Retter, A, Gschwantler-Kaulich, D, Czerwenka, K, Kroiss, R, Tea, M, Pischinger, K, Köstler, W J, Attems, J, Mueller, R, Blaukopf, C, Kubista, E, Hengstschläger, M, Singer, C F

“…BRCA1/2 mutations predispose to early onset breast and ovarian cancers. The phenotypic expression of mutant alleles, however, is thought to be modified by…”
Get full text

The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS) by Ploner, F., Lamm, W., Schur, S., Eisterer, W., Kühr, T., Lindorfer, A., Tinchon, C., Köstler, W. J., Szkandera, J., Brodowicz, T.

“…Purpose The purpose of this retrospective analysis was to assess efficacy and tolerability of trabectedin in soft tissue sarcoma (STS) in the routine clinical…”
Get full text

Acute compartment syndrome of the limb by Köstler, W., Strohm, P.C., Südkamp, N.P.

“…In this review the aetiology, clinical signs, diagnosis and therapy of the acute compartment syndrome of the limb is discussed. It is a limb- and untreated…”
Get full text

Acute compartment syndrome of the limb by Köstler, W., Strohm, P.C., Südkamp, N.P.

“…In this review the aetiology, clinical signs, diagnosis and therapy of the acute compartment syndrome of the limb is discussed. It is a limb- and untreated…”
Get full text

Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment by HUDELIST, G, KÖSTLER, W. J, ATTEMS, J, CZERWENKA, K, MÜLLER, R, MANAVI, M, STEGER, G. G, KUBISTA, E, ZIELINSKI, C. C, SINGER, C. F

“…Proteolytic cleavage of the Her-2/neu extracellular domain (ECD) has been shown to initiate receptor phosphorylation representing Her-2/neu activation in…”
Get full text

Reply to Third consensus on medical treatment of metastatic breast cancer by Köstler, W.J., Zielinski, C.C.

Get full text

Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors by Lamm, W, Schur, S, Köstler, W J, Funovics, P, Windhager, R, Amann, G, Panotopoulos, J, Pokrajac, B, Brodowicz, T

“…Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of sarcoma, with a poor outcome. MPNST are regarded as being sporadic or associated with…”
Get more information

Sarcoma of the Ewing Family in Pregnancy: A Case Report of Intrauterine Fetal Death after Induction of Chemotherapy by Schur, S., Wild, J., Amann, G., Köstler, W., Langer, M., Brodowicz, T.

“…Ewing’s sarcoma is an ultra-orphan disease (2/1,000,000/year) which requires a multimodal therapy approach in high-volume centers. Treatment consists of…”
Get full text